Seres Therapeutics Inc

NASDAQ:MCRBUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Contact Information

Headquarters

101 Cambridge Park DriveCAMBRIDGE, MA, United States 02140

Phone

617-945-9626

Fax

302-655-5049

Executives

Independent Chairman of the Board

Stephen Berenson

President, Chief Executive Officer, Interim Chief Financial Officer, Director

Eric Shaff

Chief Financial Officer, Executive Vice President

Marella Thorell

Executive Vice President, Chief Technology Officer

David Ege

Executive Vice President, Chief Scientific Officer

Matthew Henn